摘要
靶向治疗为驱动基因阳性的非小细胞肺癌(non-small-cell lung cancer,NSCLC)患者带来显著生存获益。伴随新药研发、临床试验的开展及阳性结果的获得,驱动基因阳性的NSCLC也迎来了更多的治疗选择、更优的疗效及安全性。中国临床肿瘤学会(Chinese Society of Clinical Oncology,CSCO)基于过去1年的研究进展更新指南为《中国临床肿瘤学会(CSCO)非小细胞肺癌诊疗指南2023》。本版针对驱动基因阳性的NSCLC的更新包括:伏美替尼和莫博赛替尼在表皮生长因子受体(epidermal growth factor receptor,EGFR)突变晚期NSCLC治疗中的相关更新,布格替尼、洛拉替尼和恩沙替尼在间变性淋巴瘤激酶(anaplastic lymphoma kinase,ALK)融合晚期NSCLC治疗中的相关更新以及其他靶向药物的更新。本文将对2023年CSCO NSCLC诊疗指南中驱动基因阳性的NSCLC的诊疗更新进行详细解读。
Targeted therapies have provided a substantial survival benefit for non-small-cell lung cancer(NSCLC)patients with oncogenic driver mutations.With the development of new drugs and progress of clinical trials,more targeted treatments with better efficacy and safety have become available.Chinese Society of Clinical Oncology(CSCO)has updated the CSCO guidelines for NSCLC based on the advances of the past year.Its updated points include updated recommendation of furmonertinib and mobocertinib in epidermal growth factor receptor mutated NSCLC,brigatinib and lorlatinib and ensartinib in anaplastic lymphoma kinase fusion NSCLC,and other targeted therapies.This article provides a profound and detailed interpretation of updates of the 2023 CSCO guidelines in the treatment of NSCLC with oncogenic driver mutations.
作者
邹宜丰
段建春
Chau Yi Fung;Duan Jianchun(CAMS Key Laboratory of Translational Research on Lung Cancer,State Key Laboratory of Molecular Oncology,Department of Medical Oncology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences Peking Union Medical College,Beijing 100021,China;Department of Medical Oncology,Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital,Chinese Academy of Medical Sciences/Cancer Hospital Affi liated to Shanxi Medical University,Taiyuan 030013,China)
出处
《实用肿瘤杂志》
CAS
2023年第5期427-433,共7页
Journal of Practical Oncology
基金
中国医学科学院医学与健康科技创新工程重大协同创新项目(2022-I2M-1-009)
希思科-豪森肿瘤研究基金(2021-070-ZZ)。
关键词
非小细胞肺癌
中国临床肿瘤学会
靶向治疗
表皮生长因子受体
间变性淋巴瘤激酶
non-small-cell lung cancer
Chinese Society of Clinical Oncology
targeted therapy
epidermal growth factor receptor
anaplastic lymphoma kinase
